Direct-acting Antivirals for Hepatitis C and Implication for Community Pharmacy Practice-Reference-Cited by-同舟云学术

Direct-acting Antivirals for Hepatitis C and Implication for Community Pharmacy Practice

Published:2023-07 Issue:25 Volume:29 Page:1967-1970
ISSN:1381-6128
Container-title:Current Pharmaceutical Design
language:en
Short-container-title:CPD

Author:

McEntee Sara¹,Liu Yifei²^ORCID,Mahmoudi Tahar³,Oliver Kathryn⁴,Cadwell Chad⁵

Affiliation:

1. Walgreens Health-System Pharmacy #10845, Kansas City, MO, USA

2. Division of Pharmacy Practice and Administration, University of Missouri - Kansas City School of Pharmacy, Kansas City, MO, USA

3. University of Missouri-Kansas City School of Medicine, Kansas City, MO, USA

4. Lincoln Surgical Hospital, Lincoln, NE, USA

5. Walgreens Greater Northwest Regional Office, Seattle, WA, USA

Abstract

Abstract: The treatment options for hepatitis C have undergone noteworthy advancements since direct-acting antivirals (DAAs) were introduced. The selection of a DAA therapy depends on the patient’s genotype, treatment history, concomitant comorbidities, and concurrent medications. Pharmacists have a pivotal role in providing clarification and recommendations in selecting appropriate, individualized DAAs for patients. This commentary aims to (1) provide an overview of DAAs on the market for hepatitis C, and (2) describe the implication for the care of patients with hepatitis C in a community pharmacy. Community pharmacists can establish a workflow to recommend appropriate DAA therapy, identify drug interactions, and improve medication adherence and compliance with lab appointments.

Publisher

Bentham Science Publishers Ltd.

Subject

Drug Discovery,Pharmacology

Reference26 articles.

1. McHutchison J.G.; Bacon B.R.; Owens G.S.; Making it happen: Managed care considerations in vanquishing hepatitis C. Am J Manag Care 2007,13(Suppl. 12),S327-S336

2. The Centers for Disease Control and Prevention Hepatitis C Surveillance Available from: (Accessed January 6, 2023).2020

3. McHutchison J.G.; Bacon B.R.; Chronic hepatitis C: An age wave of disease burden. Am J Manag Care 2005,11(10),S286-S295

4. Liang T.J.; Rehermann B.; Seeff L.B.; Hoofnagle J.H.; Pathogenesis, natural history, treatment, and prevention of hepatitis C. Ann Intern Med 2000,132(4),296-305

5. World Health Organization Hepatitis C Available from: